Sugi Predict

Sugi Predict / Compounds / SCHEMBL2120191

SCHEMBL2120191

SCHEMBL2120191

O=Cc1cccc2c1-c1ccccc1C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 2/20 0.47
▸ POLB P06746 1/20 0.46
▸ MEN1 O00255 2/20 0.44
▸ THRB P10828 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ BLM P54132 1/20 0.44
▸ HTR2B P41595 1/20 0.43
▸ MIF P14174 3/20 0.40
▸ BCHE P06276 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ TSHR P16473 2/20 0.38
▸ TRIM24 O15164 1/20 0.38
▸ TRIM33 Q9UPN9 1/20 0.38
▸ MAPT P10636 3/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ HPN P05981 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7641889 0.81 DRD2 (0.44) MAOAPOLBMEN1THRBKMT2A
SCHEMBL15048544 0.80 METAP1 (0.41) MAOATDP1ALDH1A1L3MBTL1TDP2
SCHEMBL68230 0.77 PNMT (0.49) MAOAMEN1THRBKMT2ATDP1
SCHEMBL29882364 0.77 PNMT (0.49) MAOAMEN1THRBKMT2ATDP1
SCHEMBL13777207 0.74 NPC1 (0.41) MAOAPOLBMEN1THRBKMT2A
SCHEMBL30403300 0.74 MAOA (0.56) MAOAPOLBMEN1KMT2ALMNA
SCHEMBL1626146 0.74 MAOA (0.52) MAOAPOLBMEN1THRBKMT2A
SCHEMBL3612898 0.73 LMNA (0.55) MAOAPOLBMEN1THRBKMT2A
SCHEMBL30086144 0.73 LMNA (0.55) MAOAPOLBMEN1THRBKMT2A
SCHEMBL8910190 0.72 LMNA (0.48) MAOAMEN1THRBKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1922171-A Pyrimidine derivatives ASKA PHARM CO LTD (JP) 2007-02-28 — — CN claimed
CN-1668918-A Methods of Drug Discovery KEDDEM BIO SCIENCE LTD (IL) 2005-09-14 — — CN claimed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 — — US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 — — US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 — — US disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 — — US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 — — EP disclosed
US-20190071407-A1 ISOXAZOLINE DERIVATIVES AS INSECTICIDES SYNGENTA CROP PROTECTION LLC (US) 2019-03-07 — — US disclosed
US-10155730-B2 Isoxazoline derivatives as insecticides SYNGENTA CROP PROTECTION, LLC (US) 2018-12-18 — — US disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 — — WO disclosed
US-20170240521-A1 PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-24 — — US disclosed
US-5204348-A Quinoline derivatives MITSUI TOATSU CHEMICALS INC. (JP) 1993-04-20 — — US disclosed
EP-0518818-A2 Arylethers, their manufacture and use as medicament CIBA-GEIGY AG (CH) 1992-12-16 — — EP disclosed
EP-0518819-A2 Amidino compounds, their manufacture and use as medicament CIBA-GEIGY AG (CH) 1992-12-16 — — EP disclosed
US-5112817-A Anticancer Drug Potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-12 — — US disclosed
EP-0363212-A2 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-04-11 — — EP disclosed
EP-0041675-B1 4-HALOGEN-5-(TRICHLOROMETHYL-PHENYL)-OXAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND RADIATION-SENSITIVE COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1985-12-11 — — EP disclosed
US-4371607-A 4-Halogeno-5-(halogenomethyl-phenyl)-oxazole derivatives, a process for the preparation thereof, and radiation-sensitive compositions containing these derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-01 — — US disclosed
EP-0041675-A2 4-Halogen-5-(trichloromethyl-phenyl)-oxazole derivatives, process for preparing them and radiation-sensitive compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1981-12-16 — — EP disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 MAOA 2194/4885POLB 930/4885MEN1 4320/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 MAOA 2194/4885POLB 930/4885MEN1 4320/4885
US-20190071407-A1 ISOXAZOLINE DERIVATIVES AS INSECTICIDES ACHE, CHRM1, ITPR3 MAOA 909/4885POLB 4453/4885MEN1 2329/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 MAOA 2194/4885POLB 930/4885MEN1 4320/4885
US-10155730-B2 Isoxazoline derivatives as insecticides ACHE, CHRM1, ITPR3 MAOA 909/4885POLB 4453/4885MEN1 2329/4885
US-20170240521-A1 PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN CNR2, CNR1, OPRL1 MAOA 2298/4885POLB 2262/4885MEN1 4854/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B MAOA 3262/4885POLB 1214/4885MEN1 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.